Legend Biotech Gets FDA Clearance for Small Cell Lung Cancer Trial
November 21 2022 - 09:47AM
Dow Jones News
By Sabela Ojea
Legend Biotech Corp. said Monday the U.S. Food and Drug
Administration cleared its investigational new drug application for
the treatment of small cell lung cancer.
The company, engaged in the discovery and development of novel
cell therapies for oncology and other indications, said the Phase 1
trial for its LB2102 drug is designed to evaluate the safety and
preliminary efficacy of the treatment while seeking to determine
the recommended dose for a Phase 2 trial.
Small cell lung cancer is the most aggressive lung tumor, and
accounts for between 10% to 15% of all newly diagnosed lung cancer
cases in the U.S., the company said.
Legend Biotech last received FDA clearance for a cancer trial in
June. The company has been working ever since on the LB1908 drug,
which treats refractory gastric, esophageal or pancreatic
cancers.
A Phase 1 trial evaluating LB1908 for advanced gastric cancers
is also ongoing in China, according to the company.
In premarket trading, shares are up 0.1% at $52.18.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 21, 2022 09:32 ET (14:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Mar 2023 to Mar 2024